Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo

BACKGROUND: The effect of anlotinib combined with epidermal growth factor receptor TKIs (EGFR-TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with acquired resistance to EGFR-TKIs and the possible molecular mechanisms are still unclear. METHODS: From April 2018 to June 2020, 20 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tao, Qian, Yuxian, Zhang, Chenfei, Uchino, Junji, Provencio, Mariano, Wang, Yan, Shi, Xiangrong, Zhang, Yan, Zhang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107735/
https://www.ncbi.nlm.nih.gov/pubmed/34012799
http://dx.doi.org/10.21037/tlcr-21-192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107735/
https://www.ncbi.nlm.nih.gov/pubmed/34012799
http://dx.doi.org/10.21037/tlcr-21-192

Ejemplares similares